← Back to Search

Toulouse hospital, France for Death (mBox Trial)

N/A
Waitlist Available
Led By Alexandre Loupy
Research Sponsored by Paris Translational Research Center for Organ Transplantation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Adult kidney recipients
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 10 years after kidney transplantation
Awards & highlights

Summary

Accurately predicting kidney recipient risk of death has a crucial interest because of the organ shortage, the need to optimize allograft allocation by identifying high-risk patients who may not benefit from a transplant and improve the clinical decision-making after transplant to ensure that each patient survives as long as possible. However, according to a literature review the investigators performed, studies attempting to develop a kidney recipient death prediction model suffer from many shortcomings, including the lack of key risk factors, use of biased registry data, small sample size, lack of external validation in different countries and subpopulations, and short follow-up. The present study thus aimed to address these limitations and develop a robust, generalizable kidney recipient death prediction model.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 10 years after kidney transplantation
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 10 years after kidney transplantation for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Patient death

Trial Design

12Treatment groups
Experimental Treatment
Group I: UCSF databaseExperimental Treatment1 Intervention
Kidney recipients data from real-world UCSF database
Group II: Toulouse hospital, FranceExperimental Treatment1 Intervention
Kidney recipients from Toulouse hospital
Group III: Saint-Louis hospital from Paris, FranceExperimental Treatment1 Intervention
Kidney recipients from Saint-Louis hospital
Group IV: Necker hospital from Paris, FranceExperimental Treatment1 Intervention
Kidney recipients from Necker hospital
Group V: Mayo Clinic from Phoenix, USExperimental Treatment1 Intervention
Kidney recipients from Mayo Clinic
Group VI: Liege hospital from BelgiumExperimental Treatment1 Intervention
Kidney recipients from Liege hospital
Group VII: Leiden University Medical Center from the NetherlandsExperimental Treatment1 Intervention
Kidney recipients from Leiden University Medical Center
Group VIII: KU Leuven, BelgiumExperimental Treatment1 Intervention
Kidney recipients from KU Leuven
Group IX: Hospital of the University of Pennsylvania from Philadelphia, USExperimental Treatment1 Intervention
Kidney recipients from Hospital of the University of Pennsylvania
Group X: Bretonneau hospital from Tours, FranceExperimental Treatment1 Intervention
Kidney recipients from Bretonneau hospital
Group XI: Bichat hospital from Paris, FranceExperimental Treatment1 Intervention
Kidney recipients from Bichat hospital
Group XII: AP-HP databaseExperimental Treatment1 Intervention
Kidney recipients data from real-world AP-HP database

Find a Location

Who is running the clinical trial?

Paris Translational Research Center for Organ TransplantationLead Sponsor
20 Previous Clinical Trials
417,147 Total Patients Enrolled
Alexandre LoupyPrincipal InvestigatorParis Institute for Transplantation and Organ Regeneration (PITOR)
5 Previous Clinical Trials
253,337 Total Patients Enrolled
~600 spots leftby Sep 2025